In particular, there have already been tremendous studies showing that high expression of CD39 and CD73 consistently correlated with poor prognosis in patients with those high incidence rates and malignant cancers such as ovarian, gastric, rectal, breast cancers (including TNBC), hepatocellular carcinoma (HCC), and non-small-cell lung cancers (NSCLCs) (68–73). Here, ENTPD1 is linked to hepatocellular carcinoma.